GSK
GSK
1,037 hedge funds and large institutions have $18.2B invested in GSK in 2026 Q2 according to their latest regulatory filings, with 108 funds opening new positions, 374 increasing their positions, 339 reducing their positions, and 84 closing their positions.
29% more first-time investments, than exits
New positions opened: 108 | Existing positions closed: 84
10% more repeat investments, than reductions
Existing positions increased: 374 | Existing positions reduced: 339
0% more funds holding
Funds holding: 1,035 → 1,037 (+2)
1.3% less ownership
Funds ownership: 18.42% → 17.12% (-1.3%)
7% less funds holding in top 10
Funds holding in top 10: 15 → 14 (-1)
12% less capital invested
Capital invested by funds: $20.7B → $18.2B (-$2.49B)
15% less call options, than puts
Call options by funds: $136M | Put options by funds: $159M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$140M |
| 2 |
JP Morgan Chase
New York
|
+$79.7M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
+$63.5M |
| 4 |
D.E. Shaw & Co
New York
|
+$53.9M |
| 5 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$45.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
-$553M |
| 2 |
Holocene Advisors
New York
|
-$305M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$272M |
| 4 |
Morgan Stanley
New York
|
-$178M |
| 5 |
Goldman Sachs
New York
|
-$170M |
GSK Hedge Fund Activity: Q2 2026 in Review
1,037 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q2 2026, worth a combined $18.2B — down 12% from $20.7B a quarter earlier.
Buyers outnumbered sellers: 108 funds opened new GSK positions and 84 closed out — a net gain of 24 holders — while 374 added to existing stakes and 339 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $140M. The largest seller was Dodge & Cox, cutting an estimated $553M.
- 1,037 institutional investors held GSK (GSK) as of Q2 2026, up from 1,035 in Q1 2026.
- Funds reported $18.2B of GSK stock for Q2 2026, down 12% quarter-over-quarter.
- 108 funds opened new GSK positions in Q2 2026 and 84 closed out, a net change of +24 holders.
- The largest GSK buyer in Q2 2026 was Point72 Asset Management, an estimated $140M added.
- The largest GSK seller in Q2 2026 was Dodge & Cox, an estimated $553M sold.
Based on aggregated 13F filings for Q2 2026.